Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.
- DOI
- 10.1586/14737140.2015.1086647
- Published
- 2015
- Container
- Expert review of anticancer therapy
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1586/14737140.2015.1086647,
title = {Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.},
author = {Alphandéry E and Grand-Dewyse P and Lefèvre R and Mandawala C and Durand-Dubief M},
year = {2015},
journal = {Expert review of anticancer therapy},
doi = {10.1586/14737140.2015.1086647},
url = {https://doi.org/10.1586/14737140.2015.1086647}
}RIS
TY - JOUR TI - Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. AU - Alphandéry E AU - Grand-Dewyse P AU - Lefèvre R AU - Mandawala C AU - Durand-Dubief M PY - 2015 JO - Expert review of anticancer therapy DO - 10.1586/14737140.2015.1086647 UR - https://doi.org/10.1586/14737140.2015.1086647 ER -
APA
E, A., P, G., R, L., C, M., & M, D. (2015). Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.. Expert review of anticancer therapy. https://doi.org/10.1586/14737140.2015.1086647
Source records
- pubmed · retrieved 2026-09-25T12:14:37.131Z